Managing the COVID-19 Drug Safety Response

Managing the COVID-19 Drug Safety Response


Current safety reporting systems cannot meet the demands of a COVID-19 response. Find out how digital transformation enables rapid understanding & management of drug safety.

What you will learn:

  • Limitations of current safety reporting systems for COVID-19 treatment and vaccination initiatives
  • Requirements for COVID-19 safety data capture to ensure signals are detected and assessed at the earliest opportunity
  • Risk reduction in particular during the rapid exposure likely during mass vaccination campaigns

Fill out the form below to download the whitepaper:

By submitting your information you are consenting to receive communications from MyMeds&Me. You may at any time 'opt out' of receiving these marketing communications by emailing